Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Revenues for APLLTD are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.695000
forwardPE 21.285692
debtToEquity 24.232000
earningsGrowth -0.120000
revenueGrowth 0.167000
grossMargins 0.731210
operatingMargins 0.114680
trailingEps 29.690000
forwardEps 43.500000

Alembic Pharmaceuticals Limited's current ratio being 1.695 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Alembic Pharmaceuticals Limited can meet its financial obligations with ease.
APLLTD's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
Alembic Pharmaceuticals Limited's low Debt-to-Equity ratio demonstrates that the company maintains a healthy balance between equity and debt, avoiding over-leverage. This suggests a low-risk financial profile, giving investors confidence in the company's stability and ability to manage its financial commitments.
With both earnings and revenue growth in low territory, APLLTD is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
APLLTD's negative gross and operating margins suggest that the company is currently facing financial difficulties, as it is unable to cover production and operational costs. This could result in significant losses if not addressed.
Alembic Pharmaceuticals Limited's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting Alembic Pharmaceuticals Limited to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


There were 11 transactions to buy APLLTD stock, with market price of 835.5045443448154.There were no buy transactions recorded during the period under consideration.Alembic Pharmaceuticals Limited's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts are favoring APLLTD with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider APLLTD as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.